Because there aren’t treatment options available for the management of progressive multiple sclerosis (MS), Patricia K. Coyle, MD, explains the challenges clinicians are faced with when treating patients who transition into a progressive stage of the disease.
Dr Coyle and Leslie Fish, PharmD, explain that although the topic of when to end therapy for patients who transition into a worsening stage is controversial, it is necessary to make personalized treatment decisions.
Dr Fish further explains how the rising costs of agents for the treatment MS further complicate management of MS and affect a clinician’s decision about when to begin or end therapy for a patient.

Episode 13 - Treatment Challenges for Progressive Disease

During this segment, Patricia K. Coyle, MD, and Leslie Fish, PharmD, raise concerns about treating patients who transition into a progressive phase of multiple sclerosis.
Published Online: January 03, 2014
View More From This Discussion
Episode 1 Episode 1 - The Changing Tides of Multiple Sclerosis: Where Do We Currently Stand?
Episode 2 Episode 2 - Elucidating the Patient's Starting Point in Care
Episode 3 Episode 3- Exploring the Etiology of Multiple Sclerosis
Episode 4 Episode 4- Characterizing Multiple Sclerosis
Episode 5 Episode 5 - Elucidating the Economic Burden of MS
Episode 6 Episode 6 - Discussing the Pathophysiology of MS
Episode 7 Episode 7 - Increased Monetary Costs of Multiple Sclerosis
Episode 8 Episode 8 - Long-Term Effects of Disease-Modifying Therapies
Episode 9 Episode 9 - Exploring Trials, Data, and the Future of Multiple Sclerosis
Episode 10 Episode 10 - Treatment Complexities
Episode 11 Episode 11 - Clinical Guidelines Vital to the Future of MS
Episode 12 Episode 12 - New MS Agents Challenged
Episode 13 Episode 13 - Treatment Challenges for Progressive Disease
Episode 14 Episode 14 - Concerns about Rising Costs of Treatment
Episode 15 Episode 15 - Controlling Drug Prices and Working at the Population Level
Episode 16 Episode 16 - MRI Scans and MS
Episode 17 Episode 17 - Conclusion: Treatment Advancements and Final Remarks